Comment on CMS-2026-2080-0001

I am writing as a healthcare consumer and advocate to voice my strong opposition to several key provisions within the proposed rule for the Medicare Drug Price Negotiation Program (CMS-4215-P / Docket CMS-2026-2080-0001). While I fully support the goal of making prescription drugs more affordable for seniors and families, I am deeply concerned that the specific regulatory mechanisms proposed here will inadvertently harm patient quality of life, stifle consumer-friendly medical advancements, and disrupt local pharmacy access. I urge CMS to revise this proposed framework to protect consumers based on the following concerns: 1. Penalizing Updates That Improve the Patient Experience As a patient, the way a medicine is delivered matters just as much as the medicine itself. The proposed expansion of product aggregation rules—which would loop "fixed-combination" updates and new delivery formats into old price negotiations—is a massive step backward for patient care. For example, when a drug transitions from requiring a multi-hour intravenous (IV) infusion at a hospital to a simple subcutaneous (under-the-skin) injection that takes five minutes, it completely transforms a patient's life. It means less time missed from work, fewer painful clinic visits, and a lower risk of hospital-acquired infections. By aggressively slashing prices on these improved reformulations by treating them as the exact same "old" drug, CMS is taking away the incentive to make medicines safer and easier for us to use. We need more patient-friendly options, not rules that freeze drug development in the past. 2. Creating Shorter Deadlines That Punish Neighborhood Pharmacies The proposal to drastically compress the timeline for submitting Prescription Drug Event (PDE) data from 30 days down to just 7 days for these selected medications will hurt everyday consumers. Independent and neighborhood pharmacies are already facing extreme financial and staffing pressures. Forcing local pharmacies to comply with a highly compressed, 7-day data transmission timeline will inevitably lead to administrative bottlenecks. When back-end insurance systems are rushed and overwhelmed, it is the patient who suffers at the pharmacy counter. This rule will lead to technical billing rejections, delayed prescription approvals, and unnecessary stress for seniors trying to pick up life-saving medications. 3. Premature Rules Before Understanding Long-Term Impact CMS is attempting to permanently cement these rigid regulations for 2029 and beyond before we have seen the full, multi-year impact of the initial negotiation rounds on consumer choices. If these price controls are locked in too early and too broadly, it could lead to insurance companies restricting their formularies or dropping coverage for specific drugs to manage their own bottom lines. Patients need regulatory stability. CMS should gather more real-world data on how these negotiations affect actual out-of-pocket costs and drug availability before making these aggressive guidelines permanent. Conclusion True consumer advocacy means balancing lower costs with access to better, safer, and more convenient healthcare. By discouraging life-improving drug updates and putting a logistical stranglehold on the pharmacies we rely on, this rule compromises patient welfare. I respectfully ask CMS to remove the fixed-combination aggregation penalties and protect pharmacy operational timelines before finalizing this regulation. Thank you for listening to consumer and patient perspectives.